These results suggest that M6A modification is crucial in GC, emphasizing the METTL3/ZMYM1/E-cadherin signaling pathway as a promising therapeutic target for approaches focused on reducing metastasis and invasion in GC (24). The gene discussed is METTL3; the disease is gastric cancer.